Growth hormone axis
GHRP-2
Also called Pralmorelin, KP-102
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in Japan.
The human evidence for GHRP-2 used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
GHRP-2 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 100–100 mcg per administration
- How often
- Every day
- Where
- Intravenous (clinical setting)
- Time to steady level
- ~2 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C45H55N9O6
- Mol. weight
- 818 Da
- CAS
- 158861-67-7
- PubChem CID
- 6918245
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for GHRP-2 describe 100–100 mcg per administration. Descriptive only, not a recommendation.
Roughly 20–30 minutes; a short-acting secretagogue.
A growth-hormone secretagogue whose human evidence is a single 100 mcg intravenous dose given as a pituitary challenge, licensed in Japan. No subcutaneous dose-ranging schedule is established, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Pralmorelin (GHRP-2) growth-hormone challenge program, JapanLicensed as a single 100 mcg intravenous growth-hormone secretagogue challenge; the human data is the single-dose challenge, not a subcutaneous schedule.